InspireMD Ltd.

168 articles with InspireMD Ltd.

• InspireMD to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021

  5/6/2021

  InspireMD, Inc. developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.

• InspireMD to Report First Quarter 2021 Financial Results on Tuesday, May 11, 2021 and Provide Corporate UpdateEarnings conference call to be held Tuesday, May 11, 2021 at 8:30 a.m. ET

  5/4/2021

  InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the “Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal first quarter 2021 financial results on Tuesday, May 11, 2021 before the market opens.

• InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board

  4/29/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of the stroke caused by carotid artery disease, announces the formation of its Scientific Advisory Board with its newly appointed chair, acclaimed interventional cardiologist, Kenneth Rosenfield, M.D.

• InspireMD Provides Corporate Update for Shareholders - Apr 19, 2021

  4/19/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, provided an update of recent corporate developments.

• InspireMD Announces 1-for-15 Reverse Stock Split

  4/14/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced a 1-for-15 reverse split of its common stock, effective as of April 26, 2021.

• InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company’s Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of Stockholders

  3/22/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of the stroke caused by carotid artery disease, issues a message to stockholders from InspireMD CEO, Marvin Slosman regarding the Company’s Special Meeting of Stockholders.

• InspireMD Announces Fourth Quarter and Year-End 2020 Financial ResultsManagement to host investor conference call today, March 9, at 8:30am ET

  3/9/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results for the fourth quarter and year ended December 31, 2020.

• InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate UpdateEarnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET

  3/2/2021

  InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announces it will report fiscal fourth quarter and year-end 2020 financial results on Tuesday, March 9, 2021 before the market opens.

• InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States

  2/24/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced that it has engaged Hart Clinical Consultants, a leading Contract Research Organization to conduct the clinical trial for its CGuard Carotid Stent System in the United States.

• InspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Registration Trial in the United States

  2/9/2021

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced the appointment of Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee as the principal investigator for its planned FDA registration trial for CGuard EPS.

• InspireMD Announces Closing of an Upsized $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

  2/8/2021

  InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the closing of an upsized underwritten public offering of units for gross proceeds of approximately $20.7 million,

• InspireMD Announces Third Quarter 2020 Financial Results

  11/9/2020

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results for the third quarter ended September 30, 2020.

• UPDATE - InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)

  11/3/2020

  InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the appointment of Andrea Tommasoli as senior vice president of global sales and marketing. Mr. Tommasoli has more than 20 years of experience in commercializing innovative medical technology solutions that improve and advance standards of care. He

• InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)

  11/3/2020

  InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announces the appointment of Andrea Tommasoli as senior vice president of global sales and marketing.

• InspireMD to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020 and Provide Corporate Update

  11/2/2020

  InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announces it will report fiscal third quarter 2020 financial results on Monday, November 9, 2020 before the market opens.

• InspireMD Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D., Ph.D., to Join Board of Directors

  10/13/2020

  InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced the addition of Gary Roubin, M.D., Ph.D., to InspireMD’s Board of Directors.

• InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide §711(a)

  10/6/2020

  InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced the appointment of Patrick Jamnik as vice president, business development and strategic initiatives.

• InspireMD Announces Christina Brennan, M.D., MBA to Serve in Advisory Role for Pivotal Study of CGuard Carotid Stent System

  9/10/2020

  InspireMD, Inc. announced the addition of Dr. Christina Brennan as a strategic advisor to the company to assist with planning and execution of a pivotal study of the CGuard™ Carotid Stent System, CARENET-III, for prevention of stroke in patients in the United States.

• InspireMD Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study of CGuard Carotid Stent System

  9/8/2020

  IDE Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Stroke Prevention in the United States

• InspireMD Announces the European Society of Cardiology 2020 “Best Poster Award” for Updated Data from the PARADIGM-EXTEND Study

  9/3/2020

  InspireMD, Inc. announces the award for Best ESC Congress Poster for the presentation of updated data from the large, long-term PARADIGM-EXTEND study of the CGuard™ Embolic Prevention System, as part of the European Society of Cardiology 2020 Carotid Update e-presentation at the European Society of Cardiology Congress 2020.